Description

Nab Paclitero 100 mg contains Paclitaxel, a taxane-based chemotherapy agent that interferes with microtubule function in cancer cells. It is commonly used as part of combination chemotherapy regimens for various solid tumors.

If formulated as nanoparticle albumin-bound paclitaxel (nab-paclitaxel), it offers improved drug delivery and reduced hypersensitivity reactions compared to conventional paclitaxel formulations.

🔬 Mechanism of Action

Paclitaxel stabilizes microtubules and prevents their normal breakdown during cell division. As a result:

• Cancer cell mitosis is disrupted
• Cell division stops
• Tumor growth slows or cancer cells die

This makes it highly effective against rapidly dividing cancer cells.

💊 Indications

Nab Paclitero 100 mg is indicated for:

• Metastatic Breast Cancer
• Non-Small Cell Lung Cancer (NSCLC)
• Pancreatic Cancer (in combination with gemcitabine)
• Ovarian Cancer
• Other solid tumors as part of combination therapy

📌 Key Features of Nab Paclitero 100 mg

• Strength: 100 mg
• Dosage Form: Intravenous injection/infusion
• Therapeutic Class: Taxane Chemotherapy Agent
• Administration: Given via IV infusion under medical supervision
• Monitoring: Regular complete blood count (CBC) and liver function tests required

⚕️ Benefits of Paclitaxel

• Effective against multiple solid tumors
• Established role in standard chemotherapy protocols
• Combination therapy compatibility
• Potential improved tolerability in nab formulation

⚠️ Precautions

• Risk of neutropenia and bone marrow suppression
• Peripheral neuropathy may occur
• Hair loss and fatigue common
• Hypersensitivity reactions possible
• Use strictly under oncologist supervision

Nab Paclitero 100 mg (Paclitaxel Injection) is a widely used chemotherapy agent in modern oncology, providing effective tumor control across various cancer types when administered under specialized medical care.